Global Fragment-Based Drug Discovery Market to Expand at a Robust CAGR of 11.5%, Forecasting Significant Growth Through 2031

Fragment-Based Drug Discovery (FBDD) has emerged as a cutting-edge approach in the early stages of drug development, offering significant advantages over traditional drug discovery methods. Unlike the conventional high-throughput screening (HTS) of large and complex molecules, FBDD employs small, low molecular weight fragments as starting points. These fragments interact with target proteins to provide critical insights for lead optimization. As the demand for more effective and novel therapeutics grows, FBDD is expected to play an increasingly crucial role in shaping the future of the pharmaceutical industry. The global FBDD market was valued at US$ 795.4 million in 2022, and it is anticipated to expand at a compound annual growth rate (CAGR) of 11.5% from 2023 to 2031, reaching a market size of approximately US$ 2.1 billion by the end of the forecast period.

Explore core findings and critical insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741

Market Size and Growth

The global FBDD market has shown significant promise, with rapid growth expected over the next decade. In 2022, the market was valued at US$ 795.4 million, and experts predict it will reach US$ 2.1 billion by 2031. This robust growth is attributed to several key factors, including the rising incidence of complex diseases, such as cancer and neurological disorders, the increasing demand for drug discovery services, and the development of advanced biophysical techniques. FBDD's ability to provide higher hit rates, enhance chemical diversity, and target previously "undruggable" proteins is fueling this upward trajectory. With the ongoing investments in R&D, as well as strategic collaborations between pharmaceutical companies and FBDD service providers, the market is poised to continue its expansion.

Competitive Landscape

The FBDD market is highly competitive, with numerous established players and a few emerging players focusing on innovative solutions to drive growth. Leading companies in the market include Alveus Pharmaceuticals Pvt. Ltd., Astex Pharmaceuticals, Charles River Laboratories International, Inc., Beactica AB, Emerald BioStructures, Inc., Crown Bioscience, Inc., Evotec AG, Proteros Fragments GmbH, Kinetic Discovery Limited, Sprint Bioscience, Sygnature Discovery, and Structure Based Design, Inc. These companies are investing heavily in research and development to stay ahead of the curve and enhance their market share. Strategic collaborations, acquisitions, and partnerships are common strategies among these players to diversify their service offerings and expand their capabilities. Furthermore, technological advancements such as protein-ligand X-ray crystallography, NMR spectroscopy, and SPR are playing a pivotal role in optimizing fragment screening processes, ensuring companies remain competitive.

Market Segmentation

The FBDD market is broadly segmented based on components, applications, and end-users, each of which contributes significantly to the market's overall growth.

By Component Type: The fragment screening segment dominated the market in 2022. This includes services like library screening, biophysical screening (such as NMR and X-ray crystallography), and computational screening. The efficiency of fragment screening, which allows for faster and more cost-effective drug discovery compared to traditional HTS methods, is a key driver of this segment's dominance.

By Application: Oncology is expected to be the leading application segment throughout the forecast period. With a significant focus on cancer research and drug development, major pharmaceutical companies are increasingly investing in FBDD for oncology research. The ability of FBDD to target cancer-associated proteins has opened new doors for identifying potential therapeutic compounds, which has resulted in its adoption in oncology-focused drug discovery.

By End-User: Pharmaceutical and biotechnology companies are expected to lead the end-user segment due to their substantial R&D budgets and strong focus on developing innovative therapeutics. These companies are increasingly utilizing FBDD services to expedite the discovery of novel drug candidates and bring them to market faster, addressing the growing patient demand for innovative therapies.

Access detailed insights by visiting our full report - https://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html

Regional Analysis

In 2022, North America dominated the global FBDD market, a trend expected to continue during the forecast period. This dominance is due to substantial investments in FBDD research and development, as well as well-established healthcare infrastructure in the U.S. and Canada. North America’s strong adoption of technological advancements and innovation positions it as a leading region in the FBDD market.

However, the Asia Pacific region is quickly emerging as a significant market for FBDD services. This is primarily due to increased investment in healthcare infrastructure and a growing focus on improving the quality of healthcare in countries like China and Japan. The region’s expanding pharmaceutical and biotechnology sectors are expected to drive demand for FBDD services in the coming years.

Future Outlook

The future outlook for the global FBDD market is highly promising. As the pharmaceutical industry continues to face challenges related to the complexity of drug discovery and the rising demand for more effective therapies, FBDD offers a solution that can streamline the drug development process. Advances in biophysical screening techniques, such as NMR spectroscopy, X-ray crystallography, and surface plasmon resonance (SPR), will likely further enhance the precision and speed of fragment screening.

More Trending Reports by Transparency Market Research –

Specialty Enzymes Market - Expected to grow at a CAGR of 6.4% from 2024 to 2034 and reach US$ 10.4 Bn by the end of 2034.

Erythropoietin Drugs Market - Estimated to grow at a CAGR of 3.8% from 2024 to 2034 and reach US$ 14.3 Bn by the end of 2034.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com    

Email: sales@transparencymarketresearch.com

Follow Us: LinkedIn| Twitter| Blog | YouTube